Ftse Mib
33.682,10
-0,45%
DAX
18.177,62
-0,90%
S&P 500
5.469,30
0,39%
NASDAQ
17.717,65
1,26%
Bitcoin
61.966,10
2,83%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Corvus Pharmaceuticals Inc (CRVS) Corvus Pharmaceuticals Inc (CRVS) Notizie

Corvus Pharmaceuticals Inc

CRVS
1,78
-0,05 (-2,73%)
Dopo l'orario di negoziazione
Ultimo aggiornamento: 23:59:00
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
17/6/202422:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202422:15EDGAR2Form 8-K - Current report
30/5/202422:02GLOBECorvus Pharmaceuticals to Present at the Jefferies Global..
07/5/202423:19EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/5/202423:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202423:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/5/202422:11EDGAR2Form 8-K - Current report
06/5/202422:01EDGAR2Form 8-K - Current report
06/5/202422:01GLOBECorvus Pharmaceuticals Provides Business Update and Reports..
02/5/202422:02GLOBECorvus Pharmaceuticals to Provide Business Update and First..
02/5/202414:30GLOBECorvus Pharmaceuticals Announces Pricing of $30.6 Million..
09/4/202422:01GLOBECorvus Pharmaceuticals Announces Initiation of..
19/3/202421:02GLOBECorvus Pharmaceuticals Provides Business Update and Reports..
19/3/202412:27IHMARKETNEWSUS Index Futures Decline Ahead of Federal Reserve Meeting,..
13/3/202421:02GLOBECorvus Pharmaceuticals to Provide Business Update and Fourth..
01/3/202423:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202414:30GLOBECorvus Pharmaceuticals Presents Soquelitinib Preclinical..
08/2/202422:27EDGAR2Form 3 - Initial statement of beneficial ownership of..
08/2/202422:05GLOBECorvus Pharmaceuticals Announces Orphan Drug Designation..
06/2/202422:05GLOBECorvus Pharmaceuticals Appoints Jeffrey Arcara as Chief..
23/1/202423:00EDGAR2Form 8-K - Current report
23/1/202423:00GLOBECorvus Pharmaceuticals Announces the Passing of Board Member..
09/12/202318:00GLOBECorvus Pharmaceuticals Presents New Interim Soquelitinib..
08/12/202322:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202322:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/11/202322:03EDGAR2Form 8-K - Current report
07/11/202322:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202322:01GLOBECorvus Pharmaceuticals Provides Business Update and Reports..
02/11/202314:15GLOBECorvus Pharmaceuticals to Present New Interim Soquelitinib..
02/11/202300:31GLOBECorvus Pharmaceuticals Announces Publication of Preclinical..
31/10/202321:02GLOBECorvus Pharmaceuticals to Provide Business Update and Report..
06/9/202322:05GLOBECorvus Pharmaceuticals Confirms Planned Initiation of..
08/8/202322:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202322:01EDGAR2Form 8-K - Current report
08/8/202322:01GLOBECorvus Pharmaceuticals Provides Business Update and Reports..
01/8/202314:30GLOBECorvus Pharmaceuticals to Provide Business Update and Report..
06/7/202318:59GLOBECorvus Pharmaceuticals Announces Publication of Preclinical..
29/6/202313:00GLOBECorvus Pharmaceuticals Presents New Ciforadenant Preclinical..
Apertura: 1,84 Min: 1,78 Max: 1,90
Chiusura: 1,83

La tua Cronologia

NASDAQ
CRVS
Corvus Pharmaceuticals
LSE
BASC
Brown Advisory Us Smalle...
NASDAQI
HX3030PI
OMX Helsinki Insurance PI
BOV
H2AI34
Hain Celestial
HITB
LWFUSD
Local World Forwarders
NASDAQ
AFAQW
AF Acquisition
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network